Australia · Delayed Price · Currency is AUD BLS Pharmaceuticals Company Description
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan.
The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands.
It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines.
The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors.
The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026.
BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
| Country | Australia |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Samuel Watson |
Contact Details
Address: Level 5 Sydney, NSW 2000 Australia | |
| Phone | 61 2 9078 8180 |
| Website | blspharma.com |
Stock Details
| Ticker Symbol | BLS |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000477796 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samuel Watson | Chief Executive Officer, MD and Executive Director |
| Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD | Chief Financial Officer and Company Secretary |
| Jason Hine | Chief Operating Officer and Executive Director |
| Macdarragh O'Neill | Head of Production of GMP and Director of BLS Wholesalers Pty |